Expedition Therapeutics

Executive Summary

Expedition Therapeutics is a preclinical-stage biotechnology company discovered in 2022, headquartered in San Diego, with a focus on neuroscience and rare diseases. The company leverages human genetics and functional genomics in a target-agnostic, phenotypic screening platform to identify novel small-molecule medicines for underserved patient populations. Backed by $165 million in total funding, Expedition aims to translate genetic insights into transformative therapies. As a private, early-stage company, it has yet to disclose specific pipeline candidates or clinical timelines, but its substantial funding and innovative approach position it as a promising player in the precision neurology space. The company's success hinges on advancing its lead programs into IND-enabling studies and demonstrating target engagement and efficacy in preclinical models.

Upcoming Catalysts (preview)

• Q3 2027IND filing for lead neuroscience program40% success
• Q4 2026Presentation of preclinical proof-of-concept data at a major scientific conference70% success
• Q2 2027Announcement of a strategic partnership or licensing deal50% success